Antihypertensive efficacy of indapamide SR in hypertensive patients uncontrolled with a background therapy: the NATIVE study^*

References

• Ezzati M, Lopez AD, Rodgers A, et al.; Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002;360: 1347–60
   Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood pressure: the JNC 7 report. JAMA 2003;289: 2560–72
   Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105–87
   PubMed Web of Science ®Google Scholar
• Williams B, Poulter NR, Brown MJ, et al.; British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18: 139–85
   Google Scholar
• Dickerson JE, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008–13
   PubMed Web of Science ®Google Scholar
• Oparil S, Silfani TN, Walker JF. Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens 2005;18(2 Pt 1):287–94
   Google Scholar
• Prevost G, Phan TM, Mounier-Vehier C, Fontaine P. Control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in a French national study (Phenomen). Diabetes Metab 2005;31: 479–85
   Google Scholar
• Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10–17
   PubMed Web of Science ®Google Scholar
• Roux O, Chapellier M, Czernichow S, et al. Determinants of hypertension control in a large French population of treated hypertensive subjects. Blood Press 2006;15:6–13
   PubMed Web of Science ®Google Scholar
• Gu Q, Paulose-Ram R, Dillon C, Burt V. Antihypertensive medication use among US adults with hypertension. Circulation 2006;113:213–21
   PubMed Web of Science ®Google Scholar
• Alonso Moreno FJ, Divison Garrote JA, Llisterri Caro JL, et al. Primary care physicians behaviour in inadequate blood pressure control. Aten Primaria 2005;36:204–10
   PubMedGoogle Scholar
• Lacourciere Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005;27:1013–21
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Malacco E, Khder Y, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005;27:578–87
   PubMed Web of Science ®Google Scholar
• Brown MJ, Cruickshank JK, Dominiczak AF, et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003;17:81–6
   PubMed Web of Science ®Google Scholar
• Sassard J, Bataillard A, McIntyre H. An overview of the pharmacology and clinical efficacy of indapamide sustained release. Fund Clin Pharmacol 2005:19:637–45
   Google Scholar
• Leonetti G. Clinical positioning of indapamide sustained release 1.5 mg in management protocols for hypertension. Drugs 2000;59\(Suppl. 2):27–40
   Google Scholar
• Mimran A, Weir MR. Angiotensin-receptor blockers and diuretics – advantages of combination. Blood Press 2005;14: 6–11
   PubMed Web of Science ®Google Scholar
• Ambrosioni E, Safar M, Degaute JP, et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group. J Hypertens 1998;16: 1677–84
   Google Scholar
• Emeriau JP, Knauf H, Pujadas JO, et al.; European Study Investigators. A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens 2001;19: 343–50
   Google Scholar
• Leonetti G, Emeriau JP, Knauf H, et al.; European Study Investigators. Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients. Curr Med Res Opin 2005;21:37–46
   Google Scholar
• London G, Schmieder R, Calvo C, Asmar R. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT study Am J Hypertens 2006:19:113–21
   PubMed Web of Science ®Google Scholar
• Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000;18: 1465–75
   Google Scholar
• Marre M, Garcia-Puig J, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR study (Natrilix SR versus Enalaril Study in hypertensive Type 2 diabetics with MicrOalbuminuRia) J Hypertens 2004;22: 1613–22
   Google Scholar
• Moser M. New-onset diabetes in the hypertension treatment trials: a point of view. Clin Hypertens (Greenwich) 2004;6: 610–13
   PubMedGoogle Scholar
• Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies. Drug Saf 2001;24:1155–65
   PubMed Web of Science ®Google Scholar
• Malacco E, Vari N, Capuano V, et al. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther 2003;25: 2765–80
   PubMed Web of Science ®Google Scholar
• Wang JG, Staessen JA. Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials. J Clin Hypertens 2003;5:66–75
   Google Scholar
• Lip GYH, Barnett AH, Bradbury A. Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management. J Hum Hypertens 2007;21:183–211
   Google Scholar